Product Description
Floxuridine (FUDR) is a pyrimidine analogue used as an antineoplastic agent, usually as a continuous hepatic arterial infusion to treat hepatic metastases from colon cancer. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Floxuridine)
Mechanisms of Action: DNA Synthesis Inhibitor,TS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Italy | United States
Approved Indications: None
Known Adverse Events: None
Company: Jazz
Company Location: DUBLIN L2 4
Company CEO: Bruce C. Cozadd
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Phase 1: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
LY01616/CT-CHN-101 | P2 |
Enrolling by invitation |
Oncology Solid Tumor Unspecified |
2024-08-31 |
57% |
NCT00695201 | P1 |
Completed |
Colorectal Cancer |
2021-06-28 |